Ofatumumab | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Ofatumumab
Health Canada Patents

AMI Lifesciences is Driven by Chemistry. Powered by People.

Contact Supplier

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Contact Supplier

Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.

Contact Supplier

Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

Contact Supplier

Quotient Sciences- Molecule to Cure. Fast.

Contact Supplier

pharmacompass-2-m-2025-08-25

Ofatumumab

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 API Suppliers, 1 JDMF

1 API Suppliers
1 JDMF

DEVELOPMENTS

83 Drugs in Development

83 Drugs in Development

FINISHED DOSAGE FORMULATIONS

7 FDF Dossiers, 2 FDA Orange Book, 1 Europe, 1 Canada, 2 Australia, 1 South Africa

7 FDF Dossiers
2 FDA Orange Book
1 Europe
1 Canada
2 Australia
1 South Africa

RELATED EXCIPIENT COMPANIES

1 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 5 Kirsch Pharma, 5 Actylis, 1 BASF, 3 Gangwal Chemicals, 1 Nanjing Bold Chemical, 1 Pluviaendo, 6 Seppic

1 Nanjing Well Pharmaceutical
1 Pfanstiehl
5 Kirsch Pharma
5 Actylis
1 BASF
3 Gangwal Chemicals
1 Nanjing Bold Chemical
1 Pluviaendo
6 Seppic

EXCIPIENTS BY APPLICATIONS

13 Parenteral, 10 Solubilizers, 4 Thickeners and Stabilizers, 3 Topical, 3 Surfactant & Foaming Agents, 3 Emulsifying Agents, 2 Film Formers & Plasticizers, 2 API Stability Enhancers, 1 Co-Processed Excipients, 1 Direct Compression, 1 Rheology Modifiers

13 Parenteral
10 Solubilizers
4 Thickeners and Stabilizers
3 Topical
3 Surfactant & Foaming Agents
3 Emulsifying Agents
2 Film Formers & Plasticizers
2 API Stability Enhancers
1 Co-Processed Excipients
1 Direct Compression
1 Rheology Modifiers

DIGITAL CONTENT

57 News #PharmaBuzz

57 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 1 Regulatory FDF Prices, 6 Annual Reports

1 US Medicaid Prescriptions
1 Regulatory FDF Prices
6 Annual Reports

PATENTS & EXCLUSIVITIES

6 Health Canada Patents

6 Health Canada Patents

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

6 All

01 6Gowling WLG (Canada) LLP

filter Patent Reset all filters

6 All

01 42502552

02 22692681

filter Product Reset all filters

6 All

01 6OFATUMUMAB

filter Dosage Reset all filters

6 All

01 6SOLUTION

filter Exp Date Reset all filters

6 All

01 42023-10-17

02 22028-07-03

Product Main Page

01

Gowling WLG (Canada) LLP

Ofatumumab

Pharmaconex

Not Confirmed

Gowling WLG (Canada) LLP

Country

Pharmaconex

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2023-10-17

Date Granted : 2019-02-12

Brand Name : ARZERRA

Patent Number : 2502552

Filing Date : 2003-10-17

Strength per Unit : 100 mg / 5 mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2023-10-17

Date Granted : 2019-02-12

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

02

Gowling WLG (Canada) LLP

Ofatumumab

Pharmaconex

Not Confirmed

Gowling WLG (Canada) LLP

Country

Pharmaconex

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2023-10-17

Date Granted : 2019-02-12

Brand Name : ARZERRA

Patent Number : 2502552

Filing Date : 2003-10-17

Strength per Unit : 1000 mg / 50 mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2023-10-17

Date Granted : 2019-02-12

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

03

Gowling WLG (Canada) LLP

Ofatumumab

Pharmaconex

Not Confirmed

Gowling WLG (Canada) LLP

Country

Pharmaconex

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2023-10-17

Date Granted : 2019-02-12

Brand Name : KESIMPTA

Patent Number : 2502552

Filing Date : 2003-10-17

Strength per Unit : 20 mg / 0.4 mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2023-10-17

Date Granted : 2019-02-12

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

Gowling WLG (Canada) LLP

Ofatumumab

Pharmaconex

Not Confirmed

Gowling WLG (Canada) LLP

Country

Pharmaconex

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-07-03

Date Granted : 2018-12-04

Brand Name : KESIMPTA

Patent Number : 2692681

Filing Date : 2008-07-03

Strength per Unit : 20 mg / 0.4 mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2028-07-03

Date Granted : 2018-12-04

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

Gowling WLG (Canada) LLP

Ofatumumab

Pharmaconex

Not Confirmed

Gowling WLG (Canada) LLP

Country

Pharmaconex

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2023-10-17

Date Granted : 2019-02-12

Brand Name : KESIMPTA

Patent Number : 2502552

Filing Date : 2003-10-17

Strength per Unit : 20 mg / 0.4ml

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2023-10-17

Date Granted : 2019-02-12

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

06

Gowling WLG (Canada) LLP

Ofatumumab

Pharmaconex

Not Confirmed

Gowling WLG (Canada) LLP

Country

Pharmaconex

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-07-03

Date Granted : 2018-12-04

Brand Name : KESIMPTA

Patent Number : 2692681

Filing Date : 2008-07-03

Strength per Unit : 20 mg / 0.4ml

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2028-07-03

Date Granted : 2018-12-04

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!